Glycopyrronium bromide prescribing across the NHS.
This is not the inhaler: standalone glycopyrronium is drooling and secretion management, much of it for children with neurodisability and adults at the end of life. 107,000 items a year at £219 an item makes it one of the most expensive routine lines in primary care; oral solutions dominate, and the licensing history explains the price.
The NHS in England dispensed 108,882 prescription items of Glycopyrronium bromide in the 12 months to July 2026, across primary care and hospitals.
Spending on Glycopyrronium bromide over those 12 months was £22.7m at net ingredient cost, the list price of what was dispensed before any discounts.
Items were up 9.3% on the previous 12 months.
82% of Glycopyrronium bromide volume moved through primary care and 18% through hospital pharmacies.
Glycopyrronium bromide ranks #5 of 13 chemical substances in Antispasmodic and other drugs altering gut motility (BNF 1.2), by items dispensed.
Among Integrated Care Boards, NHS North East and North Cumbria ICB dispensed the highest volume of Glycopyrronium bromide.
Source: NHS Business Services Authority open data (English Prescribing Data and SCMD), OGL v3.0. Items count prescriptions dispensed, not patients treated.
Diamond markers show events around this period: NICE decisions, safety alerts, supply notices, Drug Tariff moves and price concessions, new suppliers in dm+d and framework awards. Hover a marker for the date and type. The evidence behind each one, with the source quote and link, sits behind Apply.
| Month | Items | Spend (NIC) |
|---|---|---|
| July 2026 | 9,743 | £1.9m |
| June 2026 | 9,489 | £1.9m |
| May 2026 | 8,757 | £1.7m |
| April 2026 | 9,168 | £1.8m |
| March 2026 | 9,313 | £1.9m |
| February 2026 | 8,297 | £1.7m |
| January 2026 | 9,259 | £1.9m |
| December 2025 | 9,407 | £2.0m |
| November 2025 | 8,652 | £1.8m |
| October 2025 | 9,348 | £2.0m |
| September 2025 | 9,108 | £2.1m |
| August 2025 | 8,341 | £1.9m |
The same series as the chart, most recent month first. The full monthly history, as CSV, sits behind Apply.
2.2% of its class.
Glycopyrronium bromide ranks #5 of 13 chemical substances in Antispasmodic and other drugs altering gut motility (BNF 1.2), by items dispensed in July 2026. The full class league, who's gaining, and the month-by-month share movement sit behind Apply.
Average items by calendar month across the full history, indexed to the annual mean.
22 suppliers hold a live glycopyrronium bromide listing, across 131 packs.
A A H Pharmaceuticals Ltd, Accord-UK Ltd, Advanz Pharma, Alliance Healthcare (Distribution) Ltd, Aristo Pharma Ltd, Axunio Ltd, Colonis Pharma Ltd, CST Pharma Ltd, Drug Tariff Special Order, Drugsrus Ltd, Martindale Pharmaceuticals Ltd, Medihealth (Northern) Ltd, Morningside Healthcare Ltd, Novartis Pharmaceuticals UK Ltd, Novumgen Ltd, Proveca Ltd, Rosemont Pharmaceuticals Ltd, Somex Pharma, Sovereign Medical Ltd, Special Order, Strides Pharma UK Ltd, Unicorn Pharmaceuticals Ltd. In the last twelve months 1 pack was listed and 2 discontinued. Every pack, its GTIN and published list price, and each week's changes are in the full report.
A listing in the NHS Dictionary of Medicines and Devices means a product may be supplied. It says nothing about sales or market share, and the list price is the reimbursement price, not what any buyer pays. Contains information from dm+d 10.1.0, published by the NHS Business Services Authority under the Open Government Licence v3.0.
Glycopyrronium bromide across all 36 ICBs.
Every Integrated Care Board in England, shaded by how much glycopyrronium bromide its GPs dispense per head of population. Hover an ICB to name it. The ranked figures for all 36 ICBs, and the drill-down to practice level, are in the full report.
Darker shading marks where Glycopyrronium bromide is dispensed most per head of population. Exact figures for every ICB, and the drill-down to practice level, are in the full report.
Zoomed out to the 7 NHS regions.
The same 12 months rolled up to NHS England's seven regions, ranked by intensity.
The teaser view.
Three rows each. The full 36-ICB view, every prescribing organisation, every strength and the hospital picture sit below the fold, behind Apply.
- 1 NHS North East and North Cumbria ICB 10k
- 2 NHS West Yorkshire ICB 6k
- 3 NHS Surrey and Sussex ICB 6k
- – + 33 more. See the full 36-ICB table. See all →
- 1 NHS Nottingham and Nottinghamshire ICB +30.2%
- 2 NHS Bath and North East Somerset, Swindon and Wiltshire ICB +23.0%
- 3 NHS Cornwall and the Isles of Scilly ICB +19.5%
- – + 33 more. See every ICB, ranked. See all →
- 1 Glycopyrronium bromide 1mg/5ml oral solution sugar free 46%
- 2 Glycopyrronium bromide 400micrograms/ml soln sugar free 18%
- 3 Sialanar 320micrograms/ml oral solution 14%
- – + 3 more. See every strength and pack. See all →
Split of items across NHSBSA primary care and SCMD hospital dispensing.
Prescribing by deprivation.
Items per 1,000 registered patients by deprivation decile (1 = most deprived), practice deprivation weighted by where each practice's patients live. Read the shape rather than the absolute level: the most and least deprived deciles cover far fewer practices, and age structure drives much of the gradient.
The devolved nations.
| Nation | Items · 12 months | Data to |
|---|---|---|
| England | 109k | July 2026 |
| Scotland | 7k | June 2026 |
| Northern Ireland | 4k | May 2026 |
| Wales | 5k | April 2026 |
Each nation publishes its own community prescribing data, with different coding and list rules, so read these per-nation rather than as an exact UK total. Sources: NHSBSA (England), Public Health Scotland, NHS Wales Shared Services Partnership, OpenDataNI. Used under the Open Government Licence v3.0.
What open data won't tell you about glycopyrronium bromide.
A licensed paediatric product and various unlicensed preparations share this line at very different prices; cost per item reflects that mix, not one price.
Asked and answered.
Is glycopyrronium bromide prescribing rising or falling in the NHS?
Rising. England dispensed 108,882 items of Glycopyrronium bromide in the 12 months to July 2026, up 9.3% on the previous 12 months. Items count prescriptions dispensed, not patients treated, so the change can reflect dose and duration shifts as well as patient numbers.
How much does the NHS spend on glycopyrronium bromide?
£22.7m at net ingredient cost in the 12 months to July 2026. Net ingredient cost is the list price of the medicine before discounts and rebates; the NHS's final bill, especially for hospital medicines, is usually lower.
Where in England is glycopyrronium bromide prescribed most?
By raw volume, NHS North East and North Cumbria ICB dispensed the most glycopyrronium bromide in the last 12 months. Raw volume favours the biggest populations; the map on this page shades every ICB by items per head to correct for that.
How up to date is this data?
This page runs to July 2026, the most recent NHSBSA release. Prescribing data publishes roughly six to eight weeks in arrears, and DoseTrend refreshes within 48 hours of each monthly release.
The full breakdown.
Every ICB, every prescribing organisation, every strength, the hospital view with what trusts paid and who holds each framework line, Signals with their sources, and the monthly briefing PDF. The rows below are placeholders; the real tables sit behind the application.
Track glycopyrronium bromide like this, every month.
£1,500 a month per molecule. Apply and we'll pre-fill Glycopyrronium bromide for you.